Fred Hassan - 28 Oct 2025 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Reporting relationship: Director
Issuer ticker: COCP
Reported as of: 28 Oct 2025
Net transaction value: +$1,500,003
SEC form: 4
Accepted by SEC: 30 Oct 2025, 16:15:23 UTC
Prior SEC filing: 24 Jun 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Fred Hassan

Key filing fact

Fred Hassan filed Form 4 for Cocrystal Pharma, Inc. (COCP) on 30 Oct 2025.

Key facts

This page summarizes Fred Hassan's Form 4 filing for Cocrystal Pharma, Inc. (COCP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 30 Oct 2025, 16:15.

Change

Previous filing in this sequence was filed on 24 Jun 2025.
Current net transaction value: +$1,500,003.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001110744 Primary reporting owner

Hassan Fred

Relationship: Director
Address: CARET GROUP, LLC, 6010 LE LAC RD., BOCA RATON,
Signature: /s/ Fred Hassan
Signature date: 30 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COCP transaction

Common Stock

Award

Transaction value: $500,001
Shares: +359,713
Change %: +35%
Price: $1.39
Shares after: 1,383,009
Date: 28 Oct 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COCP transaction Derivative

Warrants

Award

Transaction value: $1,000,002
Shares: +719,426
Change %
Price: $1.39
Shares after: 719,426
Date: 28 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 719,426
Exercise price: $1.24
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.

Footnote F2

Includes shares of common stock issuable upon vesting of restricted stock units.